US 12,146,875 B2
Methods for categorizing and treating subjects having cystic fibrosis (CF) and at risk for severe pulmonary exacerbation
Milene Saavedra, Denver, CO (US)
Assigned to National Jewish Health, Denver, CO (US)
Filed by National Jewish Health, Denver, CO (US)
Filed on Oct. 8, 2021, as Appl. No. 17/497,090.
Application 17/497,090 is a continuation of application No. 16/704,768, filed on Dec. 5, 2019, abandoned.
Application 16/704,768 is a continuation of application No. 16/134,757, filed on Sep. 18, 2018, granted, now 10,539,558, issued on Jan. 21, 2020.
Application 16/134,757 is a continuation of application No. 14/665,331, filed on Mar. 23, 2015, granted, now 10,126,295, issued on Nov. 13, 2018.
Claims priority of provisional application 62/000,903, filed on May 20, 2014.
Claims priority of provisional application 61/968,960, filed on Mar. 21, 2014.
Prior Publication US 2022/0205987 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); G01N 33/537 (2006.01); G01N 33/68 (2006.01); G16B 40/00 (2019.01); G16B 40/30 (2019.01); G16C 99/00 (2019.01); G16H 50/30 (2018.01)
CPC G01N 33/537 (2013.01) [C12Q 1/6883 (2013.01); G01N 33/68 (2013.01); G01N 33/6893 (2013.01); G16B 40/00 (2019.02); G16B 40/30 (2019.02); G16C 99/00 (2019.02); G16H 50/30 (2018.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/54 (2013.01); G01N 2333/705 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70535 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/924 (2013.01); G01N 2333/96486 (2013.01); G01N 2400/40 (2013.01); G01N 2800/122 (2013.01); G01N 2800/125 (2013.01); G01N 2800/127 (2013.01); G01N 2800/50 (2013.01)] 5 Claims
 
1. A method of treating a subject having cystic fibrosis and at risk for severe pulmonary exacerbation, the method comprising
a. obtaining a whole blood sample from the subject;
b. detecting the mRNA expression level of each of the following genes in a gene panel consisting of: TLR2, ADAM9, PLXND1, CD163, CD36, CD64, CSPG2, IL32, HPSE, and HCA112;
c. determining the subject's risk for severe pulmonary exacerbation by calculating a risk score of mild, moderate or severe pulmonary exacerbation based on the subject's combined mRNA expression level of the genes from step (b), wherein the subject's calculated risk score correlates to a risk score for mild, moderate or severe pulmonary exacerbation; and
d. treating the subject determined to be at risk for severe exacerbation with treatments effective for treating severe pulmonary exacerbations.